



## New Range of Inhibitors



Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade physiological control on growth and survival. Consequently, small molecule kinase inhibitors show great promise as anti-cancer agents.

Particular targets for research in this area are the PI 3-kinase related pathways. PI 3-Kinases (phosphoinositide 3-kinase) are key regulators of cell signaling pathways that control various cellular processes including proliferation, motility, survival, and apoptosis. The frequent activation of the PI3 -kinase/AKT signaling pathway in cancer has fuelled intense activity in the development of new drugs that target this pathway.

To assist you with your research SYMANSIS has developed relationships with world renowned scientists to develop a unique range of kinase inhibitors covering a number of pathways. A chemically diverse range of PI 3-kinase inhibitors were recently added to the list of more than 70 compounds in the range.

Symansis also has a range of other **Inhibitors, Human Cell Expressed Proteins and Antibodies.**

For further information visit our web-site [www.symansis.com](http://www.symansis.com)



[www.symansis.com](http://www.symansis.com)

(our UK distributor is Caltag Medsystems Ltd. T: +44 (0) 1280 827460  
E: [office@caltagmedsystems.co.uk](mailto:office@caltagmedsystems.co.uk) W: [www.caltagmedsystems.co.uk](http://www.caltagmedsystems.co.uk))